Want to see FR:ALVIO full AI Analyst Report?
Valerio Therapeutics (ALVIO) AI Stock Analysis
Valerio Therapeutics
(Paris:ALVIO)
The score is driven mainly by the 2025 operational turnaround in revenue, margins and cash generation, but capped by ongoing net losses and a fragile balance sheet, with weak, oversold technical momentum and lack of valuation support from earnings or dividends reinforcing a cautious overall view.
Valerio Therapeutics (ALVIO) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 269.62M
- Dividend Yield
- ―
- Average Volume (3M)
- 917.64K
- Price to Earnings (P/E)
- -10.1
- Beta (1Y)
- -0.26
- Revenue Growth
- 203.22%
- EPS Growth
- 62.89%
- Country
- France
- Employees
- 41
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Valerio Therapeutics Business Overview & Revenue Model
Company Description
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on ta...
How the Company Makes Money
As a clinical-stage biotechnology company, Valerio Therapeutics’ monetization primarily depends on external financing and potential partnering economics tied to its drug-development programs. The company generally generates cash through (1) capital r...
Valerio Therapeutics Financial Statement Overview
Summary
Revenue grew 41% in 2025 with stable 67–71% gross margins and EBITDA turning positive, but persistent net losses, high leverage and volatile cash flows keep overall financial strength modest.
Income Statement
45NeutralBalance Sheet
35NegativeCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.55M | 2.57M | 1.79M | 1.80M | 1.44M | 4.06M |
| Gross Profit | 3.49M | 1.73M | 1.28M | 1.27M | 929.00K | 3.69M |
| EBITDA | -1.31M | 542.00K | -12.06M | -19.68M | -17.08M | -5.86M |
| Net Income | -7.05M | -4.90M | -23.93M | -20.34M | -19.56M | -5.94M |
Balance Sheet | ||||||
| Total Assets | 18.09M | 15.23M | 17.93M | 35.27M | 43.09M | 53.06M |
| Cash, Cash Equivalents and Short-Term Investments | 656.00K | 1.05M | 1.18M | 6.82M | 14.59M | 17.89M |
| Total Debt | 12.84M | 7.61M | 13.44M | 9.00M | 10.09M | 9.94M |
| Total Liabilities | 18.33M | 13.16M | 26.19M | 20.47M | 20.82M | 20.12M |
| Stockholders Equity | -233.00K | 2.08M | -8.93M | 14.80M | 22.27M | 32.94M |
Cash Flow | ||||||
| Free Cash Flow | 3.04M | 521.00K | -12.78M | -18.78M | -9.93M | -8.71M |
| Operating Cash Flow | 4.76M | 1.84M | -12.46M | -18.60M | -9.44M | -8.57M |
| Investing Cash Flow | -1.71M | -1.16M | -1.39M | -177.00K | -409.00K | -66.00K |
| Financing Cash Flow | -5.03M | -774.00K | 4.21M | 10.76M | 6.46M | 11.98M |
Valerio Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVIO, the sentiment is Positive. The current price of 0.43 is above the 20-day moving average (MA) of 0.43, below the 50-day MA of 0.57, and above the 200-day MA of 0.35, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.32 is Neutral, neither overbought nor oversold. The STOCH value of 67.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALVIO.
Valerio Therapeutics Peers Comparison
Overall Rating
FR:IPH47Neutral
FR:TNG45Neutral- FR:ALVIO43Neutral
FR:OSE43Neutral
FR:SIGHT43Neutral
FR:ALCLS42.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:IPH | 47Neutral | EUR 140.30M | -2.46 | 152.56% | ― | -29.48% | 7.91% |
| FR:TNG | 45Neutral | EUR 202.03M | -4.34 | -29.36% | ― | 189.81% | 38.50% |
| FR:ALVIO | 43Neutral | EUR 269.62M | -10.08 | -765.58% | ― | 203.22% | 62.89% |
| FR:OSE | 43Neutral | EUR 45.93M | -1.16 | -96.73% | ― | -96.25% | -197.89% |
| FR:SIGHT | 43Neutral | EUR 18.98M | -1.06 | 52.39% | ― | -610.31% | 43.88% |
| FR:ALCLS | 43Neutral | EUR 75.07M | -1.78 | -94.14% | ― | -5.98% | -8.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALVIO | Valerio Therapeutics | 0.46 | 0.36 | 373.20% | |
| FR:IPH | Innate Pharma S.A. | 1.26 | -0.35 | -21.79% | |
| FR:TNG | Transgene SA | 0.73 | -0.75 | -50.78% | |
| FR:OSE | OSE Immunotherapeutics | 1.95 | -3.78 | -65.93% | |
| FR:SIGHT | GenSight Biologics | 0.08 | -0.06 | -42.11% | |
| FR:ALCLS | Cellectis SA | 1.04 | -1.90 | -64.69% |
Valerio Therapeutics Corporate Events
Valerio Therapeutics Completes Etherna Deal to Build Integrated RNA Platform
Valerio Therapeutics has completed the acquisition of Etherna Immunotherapies, taking full control of the mRNA and lipid nanoparticle specialist to create a combined platform in targeted nucleic acid medicines. The deal, based on a €30 million...
Valerio Therapeutics accelerates RNA precision pivot with Etherna deal and new CEO
Valerio Therapeutics reported that the first half of 2026 was pivotal in its strategic refocus toward RNA‑based precision therapies, highlighted by the operational launch of InVimmune, a new subsidiary for in vivo cell therapy with an initial o...
Valerio Therapeutics to Acquire Etherna and Raises €40.25m in PIPE to Fund RNA Push
Valerio Therapeutics has signed a definitive agreement to acquire 100% of Etherna Immunotherapies NV for an enterprise value of €30 million, to be paid in cash and shares. The deal is intended to merge Etherna’s RNA and lipid nanoparticle...
Valerio Therapeutics Nears Signing of €30 Million Etherna Acquisition
Valerio Therapeutics has provided an update on its project to acquire 100% of Etherna Immunotherapies NV, following a binding offer made on July 1, 2026 that valued the target at an enterprise value of €30 million. The companies had initially s...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026